Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab

Table 2 – Clinical and molecular characteristics of relapsed patients

Patient	Age	WBC at diagnosis (x 10⁹/L)	Transcript type	Mutations (targeted sequencing)	Gene deletions (SNP array)	NGS MRD response after C1	PCR MRD response after C1	Duration of CR1 (months)	Type of relapse
#1	57	2.0	p190	IKZF1	CDKN2A/B, PAX5, VPREB1, BTG1, RB1, XBP1	Negative	CMR	8.6	Peritoneum and lymph nodes (Ph-negative)
#2	60	322.1	p190	IKZF1	CDKN2A/B, PAX5	Not done	CMR	24.5	Bone marrow
#3	44	152.6	p190	None	CDKN2A/B	Positive (1/million)	CMR	7.6	Bone marrow
#4	18	4.5	p190	None	Not done	Positive (below LOD)	CMR	11.3	Bone marrow
#5	48	95.5	p190	None	IKZF1, CDKN2A/B, PAX5, BTG1	Not done	Not done	17.0	Bone marrow + vitreous fluid
#6	28	270.5	p190	Not done	IKZF1, CDKN2A/B, PAX5, VPREB1	Not done	CMR	22.0	CNS
#7	43	12.9	p190	BCORL1	IKZF1, VPREB1	Negative	CMR	19.8	CNS
#8	49	84.9	p190	None	IKZF1, CDKN2A/B, RB1, XBP1	Not done	CMR	23.2	CNS
#9	44	236.7	p190	None	IKZF1, CDKN2A/B, XBP1	Positive (57/million)	CMR	8.5	CNS
#10	70	181.2	p210	DNMT3A, SF3B1, TET2	IKZF1	Positive (below LOD)	CMR	20.7	CNS

Abbreviations: WBC, white blood cell; SNP, single nucleotide polymorphism; NGS, next-generation sequencing; MRD, measurable residual disease; C1, cycle 1; LOD, level of detection; PCR, polymerase chain reaction; CMR, complete molecular response; CR1, first remission; Ph, Philadelphia chromosome; CNS, central nervous system

ISSN: 1756-8722